Ivabradine

Ivabradine, the active ingredient in Ivabradine, is a If channel inhibitor presented as a tablet for oral use. It reduces heart rate in patients with chronic stable angina pectoris and heart failure with reduced ejection fraction.

GNH USA supplies Ivabradine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to lower heart rate in cardiovascular disease. - Chronic stable angina pectoris: improves exercise tolerance and reduces frequency of angina episodes. - Heart failure with reduced ejection fraction: lowers resting heart rate and may lessen symptoms and hospitalisations. - Patients with sinus rhythm and resting heart rate ≥75 bpm: provides heart‑rate reduction when beta‑blocker therapy is insufficient.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below the intended therapeutic range. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Symptomatic heart block. - Persistent visual disturbances. - Elevated hepatic enzymes.

Before prescribing Ivabradine, clinicians should consider several safety aspects. - Cardiovascular assessment: confirm heart rate and sinus rhythm. - Concomitant bradycardic agents: monitor for excessive slowing of heart rate. - CYP3A4 inhibitors: avoid strong inhibitors or adjust therapy. - Severe hepatic impairment: contraindicated due to altered metabolism. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Ivabradine interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Other heart‑rate‑lowering agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of profound bradycardia. - Other If channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics causing electrolyte imbalance: may predispose to arrhythmias. - Antihypertensive agents: monitor blood pressure for additive hypotensive effect.